In the stockapocalypse that was Manic Monday, medical technology and pharma stocks got a mere slap on the wrist compared with banking stocks that received a more humiliating pants-down whipping.
It appears that pharma stocks fared better than medical device and biotech stocks. GlaxoSmithKline (NYSE:GSK) was down a mere 28 cents to close at $39.44 on Monday. Pfizer (NYSE:PFE) was down 45 cents to $16.66. Abbott Laboratories (NYSE:ABT), however, fared a little bit worse with its share price falling by $1.24 to close at $48.06.
In the world of medical devices, Boston Scientific (NYSE:BSX) came home least battered with its share price falling only 29 cents to close at $6. However, its single-digit stock price doesn’t really afford much comfort. Medtronic (NYSE:MDT) and St. Jude Medical (NYSE:STJ) both had reductions of more than $2 each to their share prices, which fell to $31.07 and $41.12 respectively. Stryker (NYSE:SYK) closed at $47.43 after a drop of $1.51, while Zimmer (NYSE:ZMH) was at $53.90, down $1.76.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Biotechnology stocks like Amgen (NASDAQ:AMGN) was cut to $49.88, a decline of $1.78 . Gilead Sciences (NASDAQ:GILD) slid only 22 cents to close at $36.82, while Biogen Idec (NASDAQ:BIIB) took a bigger hit dropping $3.29 to finish at $88.
These are just a sampling of some stocks in each sector and how they survived Manic Monday. Feel free to add how other stocks weathered the maelstrom in the comments section.
